>
Switch to:

VistaGen Therapeutics Debt-to-Revenue

: 2.19 (As of Dec. 2021)
View and export this data going back to 2011. Start your Free Trial

Debt-to-Revenue measures a company's ability to pay off its debt.

VistaGen Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2021 was $0.42 Mil. VistaGen Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2021 was $2.72 Mil. VistaGen Therapeutics's annualized Revenue for the quarter that ended in Dec. 2021 was $1.43 Mil. VistaGen Therapeutics's annualized Debt-to-Revenue for the quarter that ended in Dec. 2021 was 2.19.


VistaGen Therapeutics Debt-to-Revenue Historical Data

The historical data trend for VistaGen Therapeutics's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VistaGen Therapeutics Annual Data
Trend Mar12 Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21
Debt-to-Revenue
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 N/A N/A N/A 3.41

VistaGen Therapeutics Quarterly Data
Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Debt-to-Revenue Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.11 2.10 2.57 2.47 2.19

Competitive Comparison

For the Biotechnology subindustry, VistaGen Therapeutics's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

VistaGen Therapeutics Debt-to-Revenue Distribution

For the Biotechnology industry and Healthcare sector, VistaGen Therapeutics's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where VistaGen Therapeutics's Debt-to-Revenue falls into.



VistaGen Therapeutics Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

VistaGen Therapeutics's Debt-to-Revenue for the fiscal year that ended in Mar. 2021 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.368 + 3.351) / 1.09
=3.41

VistaGen Therapeutics's annualized Debt-to-Revenue for the quarter that ended in Dec. 2021 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.424 + 2.717) / 1.432
=2.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2021) Revenue data.


VistaGen Therapeutics Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of VistaGen Therapeutics's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


VistaGen Therapeutics Business Description

VistaGen Therapeutics logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Traded in Other Exchanges
N/A
Address
343 Allerton Avenue, South San Francisco, CA, USA, 94080
VistaGen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of a major depressive disorder in patients with an inadequate response to standard antidepressants. The PH94B is a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia; PH10 is an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression.
Executives
Saxe Jon S director FIRST HORIZON PHARMACEUTICAL CORP 660 HEMBREE PKWY STE 106 ROSWELL GA 30076
Dotson Jerrold Duane officer: VP, CFO AND SECRETARY 5 CENTERPOINTE DRIVE SUITE 400 LAKE OSWEGO OR 97035
Singh Shawn director, officer: CHIEF EXECUTIVE OFFICER C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Snodgrass H. Ralph director, officer: PRES./CHIEF SCIENTIFIC OFFICER 384 OYSTER POINT BLVD. SUITE 8 SOUTH SAN FRANCISCO CA 94080
Smith Mark Alan officer: CHIEF MEDICAL OFFICER 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Mcpartland Mark A. officer: VP CORPORATE DEVELOPMENT C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Gin Jerry B director 343 ALLERTON AVE SOUTH SAN FRANCISCO CA 94080
Underdown Brian J. director C/O LUMIRA CAPITAL INVESTMENT MANAGEMENT 141 ADELAIDE ST. WEST, SUITE 770 TORONTO ONTARIO CANADA M5H 3L5 A6 00000
Cunningham Ann Michelle director 255 N CALDWELL CIRCLE DOWNINGTOWN PA 19335
Rice A. Franklin officer: VP CORPORATE DEVELOPMENT 384 OYSTER POINT BLVD. SUITE 8 SOUTH SAN FRANCISCO CA 94080
Bonfiglio Gregory A. director 384 OYSTER POINT BOULEVARD, NO. 8 SOUTH SAN FRANCISCO CA 94080
Platinum Long Term Growth Vii, Llc 10 percent owner 152 WEST 57TH STREET 4TH FLOOR NEW YORK NY 10019
Cato Holding Co 10 percent owner 4364 SOUTH ALSTON AVENUE DURHAM NC 27713
Cato Allen Easley 10 percent owner 4364 SOUTH ALSTON AVENUE DURHAM NC 27713
Jones Stephanie director, 10 percent owner, officer: PRESIDENT 13834 W. HOYT ROAD RATHDRUM ID 83858

VistaGen Therapeutics Headlines

Other Sources

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)